PT3386591T - Moduladores de recetores nmda heteroaromáticos e suas utilizações - Google Patents

Moduladores de recetores nmda heteroaromáticos e suas utilizações

Info

Publication number
PT3386591T
PT3386591T PT168201036T PT16820103T PT3386591T PT 3386591 T PT3386591 T PT 3386591T PT 168201036 T PT168201036 T PT 168201036T PT 16820103 T PT16820103 T PT 16820103T PT 3386591 T PT3386591 T PT 3386591T
Authority
PT
Portugal
Prior art keywords
heteroaromatic
nmda receptor
receptor modulators
nmda
modulators
Prior art date
Application number
PT168201036T
Other languages
English (en)
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of PT3386591T publication Critical patent/PT3386591T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
PT168201036T 2015-12-09 2016-12-09 Moduladores de recetores nmda heteroaromáticos e suas utilizações PT3386591T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265182P 2015-12-09 2015-12-09

Publications (1)

Publication Number Publication Date
PT3386591T true PT3386591T (pt) 2020-10-01

Family

ID=57681781

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168201036T PT3386591T (pt) 2015-12-09 2016-12-09 Moduladores de recetores nmda heteroaromáticos e suas utilizações

Country Status (13)

Country Link
US (3) US10626122B2 (pt)
EP (1) EP3386591B1 (pt)
JP (1) JP7071917B2 (pt)
CY (1) CY1123359T1 (pt)
DK (1) DK3386591T3 (pt)
ES (1) ES2821010T3 (pt)
HR (1) HRP20201522T1 (pt)
HU (1) HUE051395T2 (pt)
LT (1) LT3386591T (pt)
PT (1) PT3386591T (pt)
RS (1) RS60834B1 (pt)
SI (1) SI3386591T1 (pt)
WO (1) WO2017100591A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3386591T (pt) 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
KR20210039432A (ko) 2018-08-03 2021-04-09 카덴트 테라퓨틱스, 인크. 헤테로방향족 nmda 수용체 조절제 및 이의 용도
US11358971B2 (en) * 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
WO1998000401A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
AU2001270149A1 (en) 2000-06-26 2002-01-08 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
EP1768960A1 (en) 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
TW200643015A (en) * 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
ATE523493T1 (de) * 2006-09-11 2011-09-15 Organon Nv 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
US7820649B2 (en) * 2006-09-11 2010-10-26 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
CN101583365B (zh) 2006-12-15 2012-09-26 阿布拉西斯生物科学公司 三嗪衍生物及其治疗应用
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
DK2160389T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
WO2008138126A1 (en) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
AU2008289573B2 (en) 2007-08-21 2013-05-16 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
JP5425891B2 (ja) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのキノリンおよび関連する類似体
CA2726262A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
MX2011003372A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Analogos de cromenona como modulares de sirtuina.
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EA028156B9 (ru) 2011-05-10 2018-01-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
SI3329919T1 (sl) 2011-11-11 2020-02-28 Gilead Apollo, Llc Inhibitorji ACC in njihove uporabe
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
PT3013798T (pt) 2013-06-28 2018-11-12 Beigene Ltd Compostos de ureia tricíclicos fusionados como inibidores de raf quinase e/ou dímeros de raf quinase
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
MX2016004540A (es) 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
WO2016034703A1 (en) * 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US20170313719A1 (en) 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
US20180325893A1 (en) 2015-10-16 2018-11-15 Northwestern University Subacute administration of nmda modulators alone or in combination
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
PT3386591T (pt) * 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
KR20210039432A (ko) * 2018-08-03 2021-04-09 카덴트 테라퓨틱스, 인크. 헤테로방향족 nmda 수용체 조절제 및 이의 용도

Also Published As

Publication number Publication date
LT3386591T (lt) 2020-10-12
US20210107916A1 (en) 2021-04-15
US20180362541A1 (en) 2018-12-20
US11236104B2 (en) 2022-02-01
HUE051395T2 (hu) 2021-03-01
WO2017100591A1 (en) 2017-06-15
JP7071917B2 (ja) 2022-05-19
RS60834B1 (sr) 2020-10-30
US20230023543A1 (en) 2023-01-26
ES2821010T3 (es) 2021-04-23
DK3386591T3 (da) 2020-09-28
JP2018536685A (ja) 2018-12-13
CY1123359T1 (el) 2021-12-31
US10626122B2 (en) 2020-04-21
SI3386591T1 (sl) 2020-11-30
EP3386591B1 (en) 2020-06-24
EP3386591A1 (en) 2018-10-17
HRP20201522T1 (hr) 2020-12-11

Similar Documents

Publication Publication Date Title
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240166A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL264514B (en) Spiro-lactam nmda receptor modulators and their uses
IL240164A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240163B (en) spiro-lactam modulators of the NMDA receptor and their uses
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240162A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240165A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
EP3490994C0 (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND THEIR USE
EP3558318A4 (en) NMDA RECEPTOR MODULATORS AND USES THEREOF
HUE051395T2 (hu) Heteroaromás NMDA receptor modulátorok és alkalmazásaik
HK1245259A1 (zh) 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途